Winnie C Mutai1, Marianne W Mureithi1, Omu Anzala1, Gunturu Revathi2, Brian Kullin3, Magdaline Burugu1, Cecilia Kyany'a4, Erick Odoyo4, Peter Otieno4, Lillian Musila4. 1. Department of Medical Microbiology, School of Medicine, University of Nairobi, Nairobi, Kenya. 2. Department of Pathology, Division of Medical Microbiology, Aga Khan University Hospital, Nairobi, Kenya. 3. Department of Molecular and Cell Biology, Faculty of Science, University of Cape Town, Cape Town, South Africa. 4. US Army Medical Research Directorate-Africa, Nairobi, Kenya.
Abstract
Introduction: Clostridioides difficile is a neglected pathogen in many African countries as it is generally not regarded as one of the major contributors toward the diarrheal disease burden in the continent. However, several studies have suggested that C. difficile infection (CDI) may be underreported in many African settings. The aim of this study was to determine the prevalence of CDI in hospitalized patients, evaluate antimicrobial exposure, and detect toxin and antimicrobial resistance profiles of the isolated C. difficile strains. Methods: In this cross-sectional study, 333 hospitalized patients with hospital-onset diarrhoea were selected. The stool samples were collected and cultured on cycloserine-cefoxitin egg yolk agar (CCEY). Isolates were presumptively identified by phenotypic characteristics and Gram stain and confirmed by singleplex real-time PCR (qPCR) assays detecting the species-specific tpi gene, toxin A (tcdA) gene, toxin B (tcdB) gene, and the binary toxin (cdtA/cdtB) genes. Confirmed C. difficile isolates were tested against a panel of eight antimicrobials (vancomycin, metronidazole, rifampicin, ciprofloxacin, tetracycline, clindamycin, erythromycin, and ceftriaxone) using E-test strips. Results: C. difficile was detected in 57 (25%) of diarrheal patients over the age of two, 56 (98.2%) of whom received antimicrobials before the diarrheal episode. Amongst the 71 confirmed isolates, 69 (97.1%) harbored at least one toxin gene. More than half of the toxigenic isolates harbored a truncated tcdA gene. All isolates were sensitive to vancomycin, while three isolates (2.1%) were resistant to metronidazole (MIC >32 mg/L). High levels of resistance were observed to rifampicin (65/71, 91.5%), erythromycin (63/71, 88.7%), ciprofloxacin (59/71, 83.1%), clindamycin (57/71, 80.3%), and ceftriaxone (36/71, 50.7.8%). Among the resistant isolates, 61 (85.9%) were multidrug-resistant. Conclusion: Multidrug-resistant C. difficile strains were a significant cause of healthcare facility-onset C. difficile infections in patients with prior antimicrobial exposure in this Kenyan hospital.
Introduction: Clostridioides difficile is a neglected pathogen in many African countries as it is generally not regarded as one of the major contributors toward the diarrheal disease burden in the continent. However, several studies have suggested that C. difficileinfection (CDI) may be underreported in many African settings. The aim of this study was to determine the prevalence of CDI in hospitalized patients, evaluate antimicrobial exposure, and detect toxin and antimicrobial resistance profiles of the isolated C. difficile strains. Methods: In this cross-sectional study, 333 hospitalized patients with hospital-onset diarrhoea were selected. The stool samples were collected and cultured on cycloserine-cefoxitin egg yolk agar (CCEY). Isolates were presumptively identified by phenotypic characteristics and Gram stain and confirmed by singleplex real-time PCR (qPCR) assays detecting the species-specific tpi gene, toxin A (tcdA) gene, toxin B (tcdB) gene, and the binary toxin (cdtA/cdtB) genes. Confirmed C. difficile isolates were tested against a panel of eight antimicrobials (vancomycin, metronidazole, rifampicin, ciprofloxacin, tetracycline, clindamycin, erythromycin, and ceftriaxone) using E-test strips. Results:C. difficile was detected in 57 (25%) of diarrhealpatients over the age of two, 56 (98.2%) of whom received antimicrobials before the diarrheal episode. Amongst the 71 confirmed isolates, 69 (97.1%) harbored at least one toxin gene. More than half of the toxigenic isolates harbored a truncated tcdA gene. All isolates were sensitive to vancomycin, while three isolates (2.1%) were resistant to metronidazole (MIC >32 mg/L). High levels of resistance were observed to rifampicin (65/71, 91.5%), erythromycin (63/71, 88.7%), ciprofloxacin (59/71, 83.1%), clindamycin (57/71, 80.3%), and ceftriaxone (36/71, 50.7.8%). Among the resistant isolates, 61 (85.9%) were multidrug-resistant. Conclusion: Multidrug-resistant C. difficile strains were a significant cause of healthcare facility-onset C. difficileinfections in patients with prior antimicrobial exposure in this Kenyan hospital.
Authors: Gabriel Ramírez-Vargas; Carlos Quesada-Gómez; Luis Acuña-Amador; Diana López-Ureña; Tatiana Murillo; María Del Mar Gamboa-Coronado; Esteban Chaves-Olarte; Nicholas Thomson; Evelyn Rodríguez-Cavallini; César Rodríguez Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: Papanin Putsathit; Monthira Maneerattanaporn; Pipat Piewngam; Daniel R Knight; Pattarachai Kiratisin; Thomas V Riley Journal: Antimicrob Resist Infect Control Date: 2017-06-08 Impact factor: 4.887
Authors: Deiziane V S Costa; Natalie V S Pham; Rachel A Hays; David T Bolick; Sophia M Goldbeck; Melinda D Poulter; Sook C Hoang; Jae H Shin; Martin Wu; Cirle A Warren Journal: Antimicrob Agents Chemother Date: 2022-07-21 Impact factor: 5.938
Authors: Hung Chan; Qing Li; Xiansong Wang; Wing Yingzhi Liu; Wei Hu; Judeng Zeng; Chuan Xie; Thomas Ngai Yeung Kwong; Idy Hiu Ting Ho; Xiaodong Liu; Huarong Chen; Jun Yu; Ho Ko; Raphael Chiu Yeung Chan; Margaret Ip; Tony Gin; Alfred Sze Lok Cheng; Lin Zhang; Matthew Tak Vai Chan; Sunny Hei Wong; William Ka Kei Wu Journal: Autophagy Date: 2022-01-06 Impact factor: 13.391